Cargando…

Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension

Nicardipine hydrochloride is an anti-hypertensive drug that is used off-label to treat hypertension in children. A previous oral formulation of nicardipine hydrochloride was developed using a commercial vehicle as an excipient. However, ready-to-use vehicles are prone to supply shortages, and their...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavelier, Marine, Gondé, Henri, Costa, Damien, Lamoureux, Fabien, Pereira, Tony, Buchbinder, Nimrod, Varin, Rémi, Hervouët, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963445/
https://www.ncbi.nlm.nih.gov/pubmed/36839767
http://dx.doi.org/10.3390/pharmaceutics15020446
_version_ 1784896255718064128
author Cavelier, Marine
Gondé, Henri
Costa, Damien
Lamoureux, Fabien
Pereira, Tony
Buchbinder, Nimrod
Varin, Rémi
Hervouët, Charles
author_facet Cavelier, Marine
Gondé, Henri
Costa, Damien
Lamoureux, Fabien
Pereira, Tony
Buchbinder, Nimrod
Varin, Rémi
Hervouët, Charles
author_sort Cavelier, Marine
collection PubMed
description Nicardipine hydrochloride is an anti-hypertensive drug that is used off-label to treat hypertension in children. A previous oral formulation of nicardipine hydrochloride was developed using a commercial vehicle as an excipient. However, ready-to-use vehicles are prone to supply shortages, and their composition may undergo substantial modifications. The aim of this study was to propose a new oral formulation of nicardipine hydrochloride 2 mg/mL using simple excipients. The formulation included hydroxypropylmethylcellulose, simple syrup, polysorbate 80, sodium saccharin, citrate buffer, strawberry flavor and 0.2% potassium sorbate. The uniformity of content was maintained before and after agitation. Nicardipine hydrochloride concentration assessed by HPLC-MS/MS remained above 90% for 365 days before opening and for 28 days after opening. pH and osmolality were maintained throughout the study, and no microbial contamination was observed. The uniformity of mass of the delivered doses was evaluated using four different devices. A new oral formulation of nicardipine hydrochloride 2 mg/mL was developed using simple and safe excipients. Pharmacological and clinical parameters remain to be assessed and compared with those of the previous formulation.
format Online
Article
Text
id pubmed-9963445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99634452023-02-26 Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension Cavelier, Marine Gondé, Henri Costa, Damien Lamoureux, Fabien Pereira, Tony Buchbinder, Nimrod Varin, Rémi Hervouët, Charles Pharmaceutics Article Nicardipine hydrochloride is an anti-hypertensive drug that is used off-label to treat hypertension in children. A previous oral formulation of nicardipine hydrochloride was developed using a commercial vehicle as an excipient. However, ready-to-use vehicles are prone to supply shortages, and their composition may undergo substantial modifications. The aim of this study was to propose a new oral formulation of nicardipine hydrochloride 2 mg/mL using simple excipients. The formulation included hydroxypropylmethylcellulose, simple syrup, polysorbate 80, sodium saccharin, citrate buffer, strawberry flavor and 0.2% potassium sorbate. The uniformity of content was maintained before and after agitation. Nicardipine hydrochloride concentration assessed by HPLC-MS/MS remained above 90% for 365 days before opening and for 28 days after opening. pH and osmolality were maintained throughout the study, and no microbial contamination was observed. The uniformity of mass of the delivered doses was evaluated using four different devices. A new oral formulation of nicardipine hydrochloride 2 mg/mL was developed using simple and safe excipients. Pharmacological and clinical parameters remain to be assessed and compared with those of the previous formulation. MDPI 2023-01-29 /pmc/articles/PMC9963445/ /pubmed/36839767 http://dx.doi.org/10.3390/pharmaceutics15020446 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cavelier, Marine
Gondé, Henri
Costa, Damien
Lamoureux, Fabien
Pereira, Tony
Buchbinder, Nimrod
Varin, Rémi
Hervouët, Charles
Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension
title Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension
title_full Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension
title_fullStr Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension
title_full_unstemmed Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension
title_short Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension
title_sort development of an oral liquid formulation of nicardipine hydrochloride compounded with simple excipients for the treatment of pediatric hypertension
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963445/
https://www.ncbi.nlm.nih.gov/pubmed/36839767
http://dx.doi.org/10.3390/pharmaceutics15020446
work_keys_str_mv AT caveliermarine developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension
AT gondehenri developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension
AT costadamien developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension
AT lamoureuxfabien developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension
AT pereiratony developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension
AT buchbindernimrod developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension
AT varinremi developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension
AT hervouetcharles developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension